Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Associations of CD6, TNFRSF1A, and IRF8 polymorphisms with risk of inflammatory demyelinating diseases.
Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis.
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.
Function and distribution of three types of rectifying channel in rat spinal root myelinated axons.
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.
Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone.
Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.
Exogenous schwann cells migrate, remyelinate and promote clinical recovery in experimental auto-immune encephalomyelitis.
The influence of ethnicity on the characteristics of multiple sclerosis: A local population study between Persians and Arabs.
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Glatiramer acetate (copaxone) modulates platelet activation and inhibits thrombin-induced calcium influx: possible role of copaxone in targeting platelets during autoimmune neuroinflammation.
Unusual case of gastroparesis leading to severe gastromegaly with demyelinating disease as a rare cause.
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
[Diagnosis of multiple sclerosis - the 2010 revision of the McDonald criteria.]
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.
B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.
Managing fatigue in patients with multiple sclerosis.
Genzyme’s Lemtrada™ approved in Canada for treatment of multiple sclerosis
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis.
Confounding in association studies: month of birth and multiple sclerosis.
UVB light attenuates the systemic immune response in CNS autoimmunity.

Pages